share_log

Possible Bearish Signals With LeMaitre Vascular Insiders Disposing Stock

Possible Bearish Signals With LeMaitre Vascular Insiders Disposing Stock

勒梅特微管医疗内部人员处置股票可能传递消极信号
Simply Wall St ·  09/17 10:15

In the last year, many LeMaitre Vascular, Inc. (NASDAQ:LMAT) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, if numerous insiders are selling, shareholders should investigate more.

在过去的一年中,许多勒梅特微管医疗公司(纳斯达克:LMAT)的内部人士出售了大量股份,这可能引起了股东的注意。当分析内部交易时,了解内部人士是买入还是卖出通常更有价值,因为后者传递了一个模糊的信息。然而,如果有许多内部人士卖出股票,股东应该进行更多的调查。

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

虽然在长期投资方面内部交易并非最重要的事情,但完全忽略内部交易是愚蠢的。

LeMaitre Vascular Insider Transactions Over The Last Year

勒梅特微管医疗公司近一年的内部交易情况

The Chairman & CEO, George LeMaitre, made the biggest insider sale in the last 12 months. That single transaction was for US$7.5m worth of shares at a price of US$75.94 each. That means that an insider was selling shares at slightly below the current price (US$90.00). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 4.6% of George LeMaitre's holding.

董事长兼首席执行官George LeMaitre在过去12个月中进行了最大规模的内部交易。那次交易的股票价值为750万美元,每股价格为75.94美元。这意味着内部人士在略低于当前价格(90.00美元)时出售股票。一般而言,当内部人士以低于当前价格出售股票时,我们认为这是令人沮丧的,因为这意味着他们对较低估值感到满意。虽然内部人士的卖出并不是一个积极的信号,但我们不能确定它是否意味着内部人士认为这些股票已经完全估值,所以这只是一个弱信号。值得注意的是,这次交易仅占George LeMaitre持股的4.6%。

Insiders in LeMaitre Vascular didn't buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

勒梅特微管医疗公司的内部人士在过去一年中没有购买任何股票。您可以在下面的图表中查看过去一年内的内部交易(按公司和个人分类)。如果您想知道确切的卖家、交易金额和交易时间,请直接点击下面的图表!

big
NasdaqGM:LMAT Insider Trading Volume September 17th 2024
纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克纳斯达克

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

如果你喜欢购买内部人员正在购买而不是销售的股票,那么你可能会喜欢这份免费的公司列表。(提示:它们中的大部分都被忽视了。)

Does LeMaitre Vascular Boast High Insider Ownership?

勒梅特微管医疗是否拥有高比例内部持股?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that LeMaitre Vascular insiders own 8.8% of the company, worth about US$177m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

审视一家公司内部股东的总持股可以帮助你判断他们是否与普通股东利益保持一致。通常情况下,内部持股比例越高,内部人士就越有动力长期发展公司。很高兴看到勒梅特微管医疗内部人士拥有公司的8.8%,价值约17700万美元。大多数股东会很高兴看到这种内部持股,因为它意味着管理层的激励与其他股东利益保持一致。

So What Does This Data Suggest About LeMaitre Vascular Insiders?

这些数据对勒梅特微管医疗内部人士有何暗示?

The fact that there have been no LeMaitre Vascular insider transactions recently certainly doesn't bother us. It's great to see high levels of insider ownership, but looking back over the last year, we don't gain confidence from the LeMaitre Vascular insiders selling. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

最近勒梅特微管医疗内部人士没有进行任何交易,并不让我们感到困扰。很高兴看到内部持股比例高,但回顾过去一年,勒梅特微管医疗内部人士的卖出并没有增加我们的信心。如果你像我一样,你可能会想考虑这家公司是会增长还是会缩小。幸运的是,你可以查看这份免费报告,其中显示了对其未来的分析师预测。

But note: LeMaitre Vascular may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但请注意:勒梅特微管医疗可能不是最好的股票买入选择。因此,请查看这份免费的有高roe和低债务的有趣公司名单。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发